SOJOURNIX
Sojournix, Inc. is a biotechnology company developing innovative medicines for women's health and endocrine disorders.
SOJOURNIX
Industry:
Biotechnology Health Care Medical
Founded:
2016-01-01
Address:
Arlington, Massachusetts, United States
Country:
United States
Website Url:
http://www.sojournixpharma.com
Total Employee:
11+
Status:
Closed
Contact:
(781) 795-4700
Total Funding:
70 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Microsoft Exchange Online Office 365 Mail GoDaddy DNS Google Google Cloud COVID-19 OpenResty
Similar Organizations
Fauna Bio
Fauna Bio is a biotechnology company leveraging the science of hibernation to improve healthcare for humans.
ORIG3N
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Q32 Bio
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Vascugen
Vascugen is a biotechnology company developing regenerative medicine for treatment of intractable vascular diseases.
Current Employees Featured
Founder
Investors List
Boxer Capital
Boxer Capital investment in Series C - Sojournix
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Sojournix
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Series C - Sojournix
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series C - Sojournix
RA Capital Management
RA Capital Management investment in Series C - Sojournix
Official Site Inspections
http://www.sojournixpharma.com
- Host name: 104.21.36.236
- IP address: 104.21.36.236
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Sojournix"
Sojournix - Crunchbase Company Profile & Funding
Organization. Sojournix . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Sojournix is a biotechnology company developing …See details»
Sojournix Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Sojournix. Use the PitchBook Platform to explore the full profile.See details»
Sojournix - Craft
Nov 5, 2019 Sojournix is a biotechnology company developing medicines for women's health and neuroendocrine disorders. The Company is currently focused on the development of SJX …See details»
Sojournix Company Profile | Management and Employees List
[email protected]: Sojournix Top Competitors. Company Employees Revenue Top technologies; AROG Pharmaceuticals Inc. 15: $3.2 M: SynDevRx Inc. 8: $2.2 M: Sermonix …See details»
Sojournix, Inc. Company Profile | Waltham, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Sojournix, Inc. of Waltham, MA. Get the latest business insights from Dun & Bradstreet.See details»
Sojournix - Overview, News & Similar companies | ZoomInfo.com
Nov 17, 2020 Sojournix contact info: Phone number: (617) 460-3579 Website: www.sojournixpharma.com What does Sojournix do? Sojournix is a clinical-stage …See details»
Sojournix - VentureRadar
Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. Onyx Scientific United Kingdom Privately Held Onyx provides a wide …See details»
Daniel Grau - President, Chief Executive Officer, and …
Grau co-founded and has served as Chief Executive Officer and Director at Sojournix since 2016. An experienced biotech entrepreneur and operating executive, Mr. Grau led the deal to acquire SJX-653 and has driven the rapid …See details»
Sojournix Announces Publication of Results from SJX-653 Proof-of ...
Sep 21, 2020 WALTHAM, Mass.--(BUSINESS WIRE)--Sep 21, 2020-- Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health and …See details»
Sojournix CEO Speaks Today at LSX World Congress USA - PR …
WALTHAM, Mass., Oct. 7, 2019 /PRNewswire/ -- Sojournix, a clinical stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the …See details»
Sojournix Completes $44M Series C Financing - FinSMEs
Jan 3, 2019 Sojournix, a developer of new medicines for the treatment of women's health and neuroendocrine disorders, completed a $44m Series C financingSee details»
Sojournix Advances Phase 2 Clinical Trial of SJX‑653 ... - Business …
Dec 8, 2020 To learn more about Sojournix, please visit www.sojournixpharma.com. Contacts. Media: Kathryn Morris [email protected] 914-204-6412 Release Summary.See details»
Sojournix Completes $44 Million Series C Financing
WALTHAM, Mass., Jan. 3, 2019 /PRNewswire/ -- Sojournix, a clinical stage pharmaceutical company focused on creating new medicines to transform the treatment of women's health …See details»
Sojournix Completes $44 Million Series C Financing - BioSpace
Jan 3, 2019 WALTHAM, Mass., /PRNewswire/ -- Sojournix, a clinical stage pharmaceutical company focused on creating new medicines to transform the treatment of women’s health …See details»
Sojournix Completes $44 Million Series C Financing
WALTHAM, Mass., Jan. 3, 2019 /PRNewswire/ -- Sojournix, a clinical stage pharmaceutical company focused on creating new medicines to transform the...See details»
Sojournix Completes $44 Million Series C Financing - PR Newswire
Jan 3, 2019 To learn more about Sojournix, we welcome you to visit www.sojournixpharma.com. References Avis et al. (2015) "Duration of Menopausal Vasomotor Symptoms Over the …See details»
Sojournix Announces Positive Top-Line Phase 1 Data …
WALTHAM, Mass., Feb. 13, 2019 /PRNewswire/ -- Sojournix, a clinical stage biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of …See details»
Sojournix Announces Publication of Results from SJX-653 Proof-of ...
Sep 21, 2020 To learn more about Sojournix, please visit www.sojournixpharma.com. Contacts. For media or investor inquiries: Kathryn Morris [email protected] 914-204-6412 …See details»
Sojournix Announces Initiation of Phase 2 Clinical Trial of
Feb 24, 2020 Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health and neuroendocrine disorders, today announced the initiation of …See details»
Sojournix Announces Initiation of Phase 2 Clinical Trial of SJX-653, …
Feb 24, 2020 – Clinically and Genetically Validated Non-Hormonal Mechanism of Action – WALTHAM, MA, USA I February 24, 2020 ISojournix, a clinical-stage biopharmaceutical …See details»